Publication Date:
2014-11-22
Description:
We introduce the antibody landscape, a method for the quantitative analysis of antibody-mediated immunity to antigenically variable pathogens, achieved by accounting for antigenic variation among pathogen strains. We generated antibody landscapes to study immune profiles covering 43 years of influenza A/H3N2 virus evolution for 69 individuals monitored for infection over 6 years and for 225 individuals pre- and postvaccination. Upon infection and vaccination, titers increased broadly, including previously encountered viruses far beyond the extent of cross-reactivity observed after a primary infection. We explored implications for vaccination and found that the use of an antigenically advanced virus had the dual benefit of inducing antibodies against both advanced and previous antigenic clusters. These results indicate that preemptive vaccine updates may improve influenza vaccine efficacy in previously exposed individuals.〈br /〉〈br /〉〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246172/" target="_blank"〉〈img src="https://static.pubmed.gov/portal/portal3rc.fcgi/4089621/img/3977009" border="0"〉〈/a〉 〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246172/" target="_blank"〉This paper as free author manuscript - peer-reviewed and accepted for publication〈/a〉〈br /〉〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Fonville, J M -- Wilks, S H -- James, S L -- Fox, A -- Ventresca, M -- Aban, M -- Xue, L -- Jones, T C -- Le, N M H -- Pham, Q T -- Tran, N D -- Wong, Y -- Mosterin, A -- Katzelnick, L C -- Labonte, D -- Le, T T -- van der Net, G -- Skepner, E -- Russell, C A -- Kaplan, T D -- Rimmelzwaan, G F -- Masurel, N -- de Jong, J C -- Palache, A -- Beyer, W E P -- Le, Q M -- Nguyen, T H -- Wertheim, H F L -- Hurt, A C -- Osterhaus, A D M E -- Barr, I G -- Fouchier, R A M -- Horby, P W -- Smith, D J -- 087982/Wellcome Trust/United Kingdom -- 089276/Wellcome Trust/United Kingdom -- DP1-OD000490-01/OD/NIH HHS/ -- HHSN266200700010C/PHS HHS/ -- HHSN272201400008C/PHS HHS/ -- MR/K021885/1/Medical Research Council/United Kingdom -- WT087982MA/Wellcome Trust/United Kingdom -- New York, N.Y. -- Science. 2014 Nov 21;346(6212):996-1000. doi: 10.1126/science.1256427.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK. World Health Organization (WHO) Collaborating Center for Modeling, Evolution, and Control of Emerging Infectious Diseases, Cambridge CB2 3EJ, UK. Department of Viroscience, Erasmus Medical Center, Rotterdam 3015 CE, Netherlands. ; Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK. World Health Organization (WHO) Collaborating Center for Modeling, Evolution, and Control of Emerging Infectious Diseases, Cambridge CB2 3EJ, UK. ; Oxford University Clinical Research Unit and Wellcome Trust Major Overseas Programme, Hanoi, Vietnam. ; Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK. ; WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory at the Peter Doherty Institute for Infection and Immunity, Melbourne VIC 3000, Australia. ; National Institute of Hygiene and Epidemiology, Hanoi, Vietnam. ; Oxford University Museum of Natural History, Oxford OX1 3PW, UK. ; Insect Biomechanics Group, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK. ; Department of Viroscience, Erasmus Medical Center, Rotterdam 3015 CE, Netherlands. ; World Health Organization (WHO) Collaborating Center for Modeling, Evolution, and Control of Emerging Infectious Diseases, Cambridge CB2 3EJ, UK. Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK. ; bobblewire.com, Saint Louis, MO 63112, USA. ; Abbott Laboratories, Weesp 1380 DA, Netherlands. ; Oxford University Clinical Research Unit and Wellcome Trust Major Overseas Programme, Hanoi, Vietnam. Nuffield Department of Clinical Medicine, Centre for Tropical Medicine, University of Oxford, Oxford OX3 7BN, UK. ; WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory at the Peter Doherty Institute for Infection and Immunity, Melbourne VIC 3000, Australia. Melbourne School of Population and Global Health, University of Melbourne, Parkville VIC 3010, Australia. ; Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK. World Health Organization (WHO) Collaborating Center for Modeling, Evolution, and Control of Emerging Infectious Diseases, Cambridge CB2 3EJ, UK. Department of Viroscience, Erasmus Medical Center, Rotterdam 3015 CE, Netherlands. dsmith@zoo.cam.ac.uk.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/25414313" target="_blank"〉PubMed〈/a〉
Keywords:
Antibodies, Viral/blood/*immunology
;
Antigenic Variation/genetics/immunology
;
Evolution, Molecular
;
Humans
;
Influenza A Virus, H3N2 Subtype/genetics/*immunology
;
Influenza Vaccines/*immunology
;
Influenza, Human/blood/*immunology/prevention & control
;
*Vaccination
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
